TGFB2 and prostate carcinoma: In order to validate the novel cis-pQTL for TGF-β2 identified in our analysis (rs11118119, chr1:218693872; A > G), we tested the association between rs11118119 and TGF-β2 levels in 538 castration-resistant prostate cancer patients from CALGB 90401 and 216 advanced pancreatic cancer patients from CALGB 80303 [13].